story of the week
Efficacy and Safety of Upadacitinib in Patients With Moderate to Severe Atopic Dermatitis
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
JAMA Dermatology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Efficacy and Safety of Upadacitinib in Patients With Moderate to Severe Atopic Dermatitis: Analysis of Follow-up Data From the Measure Up 1 and Measure Up 2 Randomized Clinical Trials
JAMA Dermatol 2022 Mar 09;[EPub Ahead of Print], EL Simpson, KA Papp, A Blauvelt, CY Chu, HC Hong, N Katoh, BM Calimlim, JP Thyssen, AS Chiou, R Bissonnette, LF Stein Gold, C Wegzyn, X Hu, M Liu, J Liu, AR Tenorio, AD Chu, E Guttman-YasskyFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.